Takeda Pharmaceutical filed a WARN Act notice confirming 634 U.S. job cuts. Of these, 247 positions are at its Cambridge, Massachusetts headquarters. The company's board approved a restructuring targeting ¥200 billion in gross savings. These savings are intended to fund upcoming dr-g launches and pipeline work. The cuts address revenue shortfalls following Vyvanse genericization.
https://www.ctol.digital/news/takeda-1-3b-restructuring-layoffs-investors